Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In an interview with the ...

A SanegeneBio researcher at work in the company's lab. Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs ...

Explore groundbreaking technological advancements in this video featuring next-gen innovations like the DelFly Nimble flapping-wing robot, sustainable electric vehicles, private space stations, ...

Genentech, which is expanding a biomanufacturing campus in Holly Springs, N.C., to roughly $2 billion, announced the mid-execution investment increase on Jan. 20 as construction on the project ...

Genentech is significantly growing its bet on Harvard University’s Allston research district, tripling its planned footprint at the Enterprise Research Campus in a move that cuts against the grain of ...

Tishman Speyer and Breakthrough Properties secured a lease expansion for a planned innovation center at the Harvard Enterprise Research Campus in Allston. Roche Genentech will triple its size at the ...

Genentech will more than double the initial investment in a state-of-the-art biomanufacturing facility in Holly Springs to approximately $2 billion, bolstering Roche and Genentech’s $50 billion ...

The facility, based in Holly Springs, North Carolina is set to be operational by 2029 and will produce next-generation treatments for metabolic conditions, such as obesity. Sign up here. The ...

Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion. The biotechnology company, a Roche subsidiary, said ...

Jan 20 (Reuters) - Roche's Genentech ‌said on Tuesday ‌it will more than double its initial investment in a biomanufacturing ‍facility in North Carolina to about $2 billion, as the ⁠companies look to ...

Biotechnology company Genentech is growing its plans to develop obesity drugs in the Triangle. The San Francisco-based drugmaker said Tuesday that it plans to invest about $2 billion at a planned ...